ArticleCureus2025
Comparison of the Effectiveness of Tamoxifen and Mitomycin C in the Prevention of Recurrent Urethral Stricture Following Internal Optical Urethrotomy (IOU): A Randomized Controlled Trial.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Internal optical urethrotomy (IOU) is a common surgical procedure for treating anterior urethral strictures, but recurrence remains a significant concern. The aim of the study is to compare the effectiveness of oral tamoxifen versus mitomycin C (MMC) in preventing recurrence and improving functional outcomes following IOU for anterior urethral stricture. This prospective, randomized controlled trial enrolled 60 male patients with anterior urethral strictures ≤2 cm in length. Participants were randomized 1:1 to receive oral tamoxifen or MMC immediately following IOU. Outcomes assessed at baseline, three months, and six months included the International Prostate Symptom Score (IPSS) as the primary outcome, and secondary measures, including maximum urinary flow rate (Qmax), stricture morphology on retrograde urethrogram, recurrence rate, and recurrence-free period. Recurrence-free period was analyzed separately using Kaplan-Meier analysis. Statistical analysis used the independent-samples t-test, Chi-square test, and Kaplan-Meier analysis, with p <0.05 considered significant. Baseline characteristics were similar between groups. At three months, both groups showed significant improvement in IPSS and Qmax, with no intergroup difference. At six months, tamoxifen patients had significantly lower IPSS (12.33 ± 2.29 vs. 19.23 ± 3.66; p < 0.001), higher Qmax (11.22 ± 1.14 vs. 7.77 ± 0.91 mL/s; p < 0.001), and narrower stricture width (1.76 ± 0.28 vs. 3.07 ± 0.38 mm; p < 0.001) than MMC patients. Recurrence occurred in 23.3% of tamoxifen and 20.0% of MMC patients (p = 0.787). Kaplan-Meier analysis showed no significant difference in recurrence-free period (p > 0.05). Both tamoxifen and MMC improved urinary function after IOU, but tamoxifen provided superior functional improvement at six months, despite similar recurrence rates. These findings support further evaluation of tamoxifen as an adjuvant to IOU in larger, long-term trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.